New Alzheimer's drug candidate takes first step in human safety trial
Disease control
Not yet recruiting
This study tests a single intravenous dose of an experimental drug called CGB3002 in healthy adults aged 18 to 55. The main goal is to see if the drug is safe and how the body processes it. This is a first step toward possibly developing a treatment for Alzheimer's disease.
Phase: PHASE1 • Sponsor: ChainGen Biopharma Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC